Storia in 3 fonti

Oculis’ eye drops for diabetic macular edema flunk Phase 3 test

Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials.

Raccontata da

endpoints.news

benzinga.com

healio.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 g fa

Oculis’ eye drops for diabetic macular edema flunk Phase 3 test

Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials.

originale

healio.com23 h fa

Diabetic macular edema eye drop from Oculis fails to meet primary endpoint

Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary endpoint in a phase 3 program, according to a press release.The DIAMOND program included two…

Leggi questa versione → originale

Timeline cronologica

lunedì 1 giugno 2026·endpoints.news
Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials.
lunedì 1 giugno 2026·benzinga.com
Why Is Oculis Stock Sinking Monday? - Oculis Holding (NASDAQ:OCS)
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to meet the primary endpoint.

Oculis’ eye drops for diabetic macular edema flunk Phase 3 test

Diabetic macular edema eye drop from Oculis fails to meet primary endpoint

Timeline cronologica

Oculis’ eye drops for diabetic macular edema flunk Phase 3 test

Why Is Oculis Stock Sinking Monday? - Oculis Holding (NASDAQ:OCS)

Why Is Oculis Stock Sinking Monday? - Oculis Holding (NASDAQ:OCS)

Diabetic macular edema eye drop from Oculis fails to meet primary endpoint